Clinical Impact of the Presence of a Diffuse Large B-Cell Lymphoma (DLBCL) Component in the Outcome of Untreated Patients with Follicular Lymphoma (FL)

被引：0
|
作者：
Magnano, Laura
Dlouhy, Ivan
Balague, Olga
Rivas-Delgado, Alfredo
Rovira, Jordina
Karube, Kennosuke
Gonzalez, Blanca
Martinez-Trillos, Alejandra
Martinez, Antonio
Delgado, Julio
Gine, Eva
Villamor, Neus
Campo, Elias
Lopez-Guillermo, Armando
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3043.3043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3043
引用
收藏
页数：6
相关论文
共 50 条
  • [1] PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL
    Magnano, L.
    Balague, O.
    Dlouhy, I.
    Rovira, J.
    Karube, K.
    Rivas, A.
    Gonzalez, B.
    Martinez-Trillos, A.
    Martinez, A.
    Delgado, J.
    Gine, E.
    Villamor, N.
    Campo, E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2016, 101 : 273 - 274
  • [2] Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma
    Magnano, L.
    Balague, O.
    Dlouhy, I.
    Rovira, J.
    Karube, K.
    Pinyol, M.
    Rivas-Delgado, A.
    Costa, D.
    Martinez-Trillos, A.
    Gonzalez-Farre, B.
    Martinez-Pozo, A.
    Gine, E.
    Colomer, D.
    Delgado, J.
    Villamor, N.
    Campo, E.
    Lopez-Guillermo, A.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2799 - 2805
  • [3] PRAMS Expression in Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)
    Perez, M.
    Shafer, J. A.
    Curry, C.
    Zu, Y.
    Ewton, A.
    Dotti, G.
    Chang, C.
    MODERN PATHOLOGY, 2009, 22 : 280A - 281A
  • [4] PRAME Expression in Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)
    Perez, M.
    Shafer, J. A.
    Curry, C.
    Zu, Y.
    Ewton, A.
    Dotti, G.
    Chang, C.
    LABORATORY INVESTIGATION, 2009, 89 : 280A - 281A
  • [5] Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)
    Nowakowski, Grzegorz S.
    Maurer, Matthew J.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Macon, William R.
    Ristow, Kay M.
    Allmer, Cristme
    Stager, Susan L.
    Witzig, Thomas E.
    Cerhan, James R.
    BLOOD, 2008, 112 (11) : 219 - 219
  • [6] Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
    Herrera, A.
    Goy, A.
    Mehta, A.
    Ramchandren, R.
    Pagel, J.
    Svoboda, J.
    Guan, S.
    Hill, J.
    Kwei, K.
    Liu, E.
    Phillips, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E18
  • [7] Risk and clinical implications of transformation of follicular lymphoma (FL) to diffuse large cell B-cell lymphoma (tFL).
    Montoto, S
    Davies, AJ
    Matthews, J
    Calaminici, M
    Norton, AJ
    Amess, J
    Vinnicombe, S
    Rohatiner, AZS
    Lister, A
    BLOOD, 2005, 106 (11) : 179A - 179A
  • [8] Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma
    Pon, Julia R.
    Marra, Marco A.
    BLOOD, 2016, 127 (02) : 181 - 186
  • [9] Clinicopathologic Analysis of Follicular Lymphoma (FL) Patients with Coexisting Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Rituximab-Containing Chemotherapy
    Fukuhara, Suguru
    Maruyama, Dai
    Miyamoto, Ken-ichi
    Kim, Sung-Won
    Watanabe, Takashi
    Kobayashi, Yukio
    Taniguchi, Hirokazu
    Maeshima, Akiko Miyagi
    Tobinai, Kensei
    BLOOD, 2012, 120 (21)
  • [10] Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)
    Marciscano, Ariel E.
    Gupta, Neel
    Zhang, Zhigang
    Teruya-Feldstein, Julie
    Noy, Ariela
    BLOOD, 2008, 112 (11) : 310 - 310
12345